A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer

STATUS

Recruiting
participants needed

400
sponsor

Hoffmann-La Roche

Send

Updated on 19 February 2024

See if I qualify

cancer

measurable disease

atezolizumab

carboplatin

solid tumour

lung cancer

etoposide

maintenance therapy

solid neoplasm

extensive stage small cell lung cancer

small cell lung cancer

tiragolumab

extensive stage sclc

Summary

This study will evaluate the efficacy of tiragolumab plus atezolizumab and carboplatin and etoposide (CE) compared with placebo plus atezolizumab and CE in participants with chemotherapy-naive extensive-stage small cell lung cancer (ES-SCLC). Eligible participants will be randomized in a 1:1 ratio to receive one of the following treatment regimens during induction phase:-

Arm A: Tiragolumab plus atezolizumab and CE
Arm B: Placebo plus atezolizumab and CE

Following the induction phase, participants will continue maintenance therapy with either atezolizumab plus tiragolumab (Arm A) or atezolizumab plus placebo (Arm B).

Details

Condition	Small Cell Lung Cancer, Small Cell Lung Cancer
Age	18years - 100years
Treatment	Placebo, Atezolizumab, Carboplatin, Etoposide, Tiragolumab
Clinical Study Identifier	NCT04256421
Sponsor	Hoffmann-La Roche
Last Modified on	19 February 2024

How understandable was the trial content above?

Hard to understand

Easy to understand

Eligibility		Yes	No	Not Sure
Inclusion Criteria
	Histologically or cytologically confirmed extensive-stage small cell lung cancer (ES-SCLC)
	No prior systemic treatment for ES-SCLC
	Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
	Measurable disease, as defined by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)
	Adequate hematologic and end-organ function
	Treatment-free for at least 6 months since last chemo/radiotherapy, among those treated (with curative intent) with prior chemo/radiotherapy for limited-stage SCLC
Exclusion Criteria
	Symptomatic or actively progressing central nervous system (CNS) metastases
	Malignancies other than small cell lung cancer (SCLC) within 5 years prior to randomization, with the exception of those with a negligible risk of metastasis or death treated with expected curative outcome
	Active or history of autoimmune disease or immune deficiency
	History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan
	Positive test result for human immunodeficiency virus (HIV)
	Active hepatitis B or hepatitis C
	Severe infection at the time of randomization
	Treatment with any other investigational agent within 28 days prior to initiation of study treatment
	Prior treatment with CD137 agonists or immune checkpoint blockade therapies, anti-CTLA-4, anti-TIGIT, anti-PD-1, and anti-PD-L1 therapeutic antibodies
	Treatment with systemic immunostimulatory agents within 4 weeks or 5 drug elimination half-lives prior to randomization

How to participate?

Step 1 Connect with a study center

Select a site
Send a message

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Primary Contact

I am at least 18 years old.

By sending a message, I agree to share my information with the study team for the selected site and consent to receive emails and text messages for trial updates, notifications, and related communication. TrialX values your privacy; your information will be handled in accordance with our Privacy Policy

Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

extensive stage small cell lung cancer

small cell lung cancer

tiragolumab

extensive stage sclc

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Study Definition

Wikipedia

A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer